Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus

Biologics: Targets and Therapy

Volumn 5, Issue , 2011, Pages 21-31

  Sticherling, Michael ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Calcineurin inhibitors; Cutaneous lupus erythematosus; Systemic therapy; Topical therapy

Indexed keywords

AZATHIOPRINE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CHLOROQUINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; DAPSONE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PLACEBO; PREDNICARBATE; RETINOID; SUNSCREEN; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; CYTOPLASM; DERMATOMYOSITIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MEDICAL DECISION MAKING; PHOTOSENSITIVITY; PROTECTIVE CLOTHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN EXAMINATION; SKIN IRRITATION; SKIN LUPUS ERYTHEMATOSUS; SKIN PROTECTION; SKIN PRURITUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

EID: 79953227742     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S9806     Document Type: Review

References (90)

1. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT, eds. Cutaneous Manifestations of Rheumatic Diseases. Philadephia: Williams & Wilkins; 2003: 15-64.
2. Rothfeld N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006;24: 348-362.
3. Kuhn A, Ruzicka T. Classifcation of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous Lupus Erythematosus. Heidelberg: Springer; 2004:53-58.
4. Tebbe B, Orfanos CE. Prognosis of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Heidelberg: Springer; 2004. p. 187-204.
5. Renner R, Sticherling M. The different faces of cutaneous lupus erythematosus. G Ital Dermatol Venereol. 2009;144:135-147
6. Sticherling M, Bonsmann G, Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. J Deutsch Dermatol Ges. 2008;6:48-61.
7. Gilliam JN. The cutaneous signs of lupus erythematosus. Cont Educ Fam Phys. 1977;6:37-40.
8. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4: 471-475.
9. Provost TT. Nonspecifc cutaneous manifestations of systemic lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Heidelberg: Springer; 2004:93-106.
10. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15:757-761.
11. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301:65-70.
12. Massone C, Kodama K, Salmhofer W, et al. Lupus erythemtaosus panniculitis (lupus profundus): clinical, histopathological and molecular analysis of nine cases. J Cutan Pathol. 2005;32:396-404.
13. Requena L, Sanchez YE. Panniculitis (Part II). Mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-361.
14. Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Deutsch Dermatol Ges. 2007;5: 1124-1140.
15. Lee-Kirsch MA, Gong M, Schulz H, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet. 2006;79:731-737.
16. Ruiz H, Sanchez JL. Tumid lupus erythematosus. Am J Dermatopathol. 1999;21:356-360.
17. Kuhn A, Bijl M. Pathogenesis of cutaneous lupus erythematosus. Lupus. 2008;17:389-393.
18. Mond CB, Peterson MG, Rothfeld NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum. 1989;32:202-204.
19. Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical fndings. Autoimmun Rev. 2005;4: 219-223.
20. Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol. 2001;144:958-966.
21. Kuhn A, Beissert S. Photosensitivity in lupus erythematosus. Autoimmunity. 2005;38:519-529.
22. Kuhn A, Herrmann M, Kleber S, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 2006;54:939-950.
23. Cardinali C, Caproni M, Fabbri P. The composition of the lupus band test (LBT) on the sun-protected non-lesional (SPNL) skin in patients with cutaneous lupus erythematosus (CLE). Lupus. 1999;8: 755-760.
24. Gaines E, Werth V P. Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res. 2008;300(1):3-9.
25. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889-894.
26. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol. 2008;144:173-180.
27. Kuhn A, Kuehn E, Meuth AM, et al. Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2009;8:702-712.
28. Ting W W, Sontheimer RD. Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus. 2001;10:171-184.
29. Lehmann P. Topical treatment of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Heidelberg: Springer; 2005:337-345.
30. Ermann J, Bermas BL. The biology behind the new therapies for SLE. Int J Clin Pract. 2007;61:2113-2119.
31. Reinhold U, Buttgereit F. High dosage steroid pulse therapy. Is there an indication in dermatology? Hautarzt. 2000;51:738-745.
32. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2002; 109:1377-1382.
33. Ochsendorf FR. Antimalarials. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Heidelberg: Springer; 2004. p. 347-372.
34. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Hydroxy- chloroquine in systemic lupus erythematosus. Lancet. 2007;369(9569): 1257-1258.
35. Böhm I, Bruns A, Schupp G, et al. ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapsone. Hautarzt. 1998;49:403-407.
36. Böhm I, Wenzel J. FACS monitoring of lymphocyte-subsets in patients with discoid and subacute-cutaneous lupus erythematosus receiving low-dose methotrexate. Scan J Rheumatol. 2002;31:216-220.
37. Schanz S, Ulmer A, Rassner G, et al. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol. 2002;147:174-178.
38. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythema-tosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol. 2001;45:142-144.
39. Tu Y, Peng X, Wang L, et al; MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus. 2008;17:622-629.
40. Boehncke WH, Ochsendorf F, Paeslack I, et al. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol. 2002;12:577-580.
41. Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology. 2007;215(Suppl 1):45-54.
42. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80: S40-S45.
43. Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol. 2008; 22:1-6.
44. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003;17:493-503.
45. Goto T, Nakagawa H. Development of tacrolimus ointment. In: Ruzicka T, Reitamo S, editors. Tacrolimus Ointment. A topical immunomodulator for atopic dermatitis. Heidelberg: Springer; 2004: 81-98.
46. Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of a topic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63:742-750.
47. Woo DK, James WD. Topical tacrolimus: a review of its uses in dermatology. Dermatitis. 2005;16:6-21.
48. De Prost Y. Clinical experience in children. In: Ruzicka T, Reitamo S, editors. Tacrolimus Ointment. A topical immunomodulator for atopic dermatitis. Heidelberg: Springer; 2004. p. 161-183.
49. Reitamo S. Clinical experience in adults. In: Ruzicka T, Reitamo S, editors. Tacrolimus Ointment. A topical immunomodulator for atopic dermatitis. Heidelberg: Springer; 2004. p. 129-160.
50. Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a.2000 patient study. J Eur Acad Dermatol Venereol. 2008;22: 195-203.
51. Dissemond J, Goos M, Wagner SN. Pimecrolimus (SDZ ASM 981). Current state of research. Dtsch Med Wochenschr. 2002;127: 1199-1203.
52. Hoetzenecker W, Ecker R, Kopp T, et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with a topic dermatitis. J Allergy Clin Immunol. 2005;115: 1276-1283.
53. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol. 2004;122: 673-684.
54. Meingassner JG, Kowalsky E, Schwendinger H, et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol. 2003;149:853-857.
55. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study. Br J Dermatol. 2001;144:507-513.
56. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24:985-994.
57. Billich A, Aschauer H, Aszodi A, et al. Percutaneous absorption of drugs used in a topic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269: 29-35.
58. Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ. 2005;172:1179-1180.
59. Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301:93-98.
60. Walker SL, Kirby B, Chalmers RJ. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol. 2002;147:405-406.
61. Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12:50-52.
62. Böhm M, Gaubitz M, Luger TA, et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology. 2003;207:381-385.
63. Bacman D, Tanbajewa A, Megahed M, et al. Topical treatment with tacrolimus in lupus erythematosus tumidus. Hautarzt. 2003;54: 977-979.
64. Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol. 2003;148:353-356.
65. De la Rosa Carrillo D, Christensen OB. Treatment of chronic discoid lupus erythematosus with topical tacrolimus. Acta Derm Venereol. 2004;84(3):233-234.
66. Drüke A, Gambichler T, Altmeyer P, et al. 0.1% Tacrolimus ointment in a patient with sub acute cutaneous lupus erythematosus. J Dermatolog Treat. 2004;15:63-64.
67. Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology. 2004;43:1383-1385.
68. Meller S, Bruch-Gerharz D, Ruzicka T, et al. Topische Behandlung des subakut-kutanen Lupus erythematodes mit Tacrolimus. Hautarzt. 2005;56:368-369.
69. Heffernan M P, Nelson MM, Smith DI, et al. 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol. 2005; 141:1170-1171.
70. Sugano M, Shintani Y, Kobayashi K, et al. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol. 2006;33:887-891.
71. Von Pelchrzim R, Schmook T, Friedrich M, et al. Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. Int J Dermatol. 2006;45:84-85.
72. Tzung TY, Liu YS, Chang H W. Tacrolimus vs clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol. 2007; 156:191-192.
73. Cooper RM, Butler DF, Ghali F, et al. Periorbital cutaneous neonatal lupus. Skinmed. 2007;6(3):145-146.
74. Madan V, August PJ, Chalmers RJ. Effcacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol. 2010;35:27-30.
75. Kawachi Y, Taguchi S, Fujisawa Y, Furuta J, Nakamura Y, Ishii Y, Otsuka F. Linear Childhood Discoid Lupus Erythematosus Following the Lines of Blaschko: Successfully Treated with Topical Tacrolimus. Pediatr Dermatol. 2010 Sep 1. [Epub ahead of print]
76. Han Y W, Kim HO, Park SH, Park YM. Four cases of facial discoid lupus erythematosus successfully treated with topical pimecrolimus or tacrolimus. Ann Dermatol. 2010;22:307-311.
77. Zabawski E. Treatment of cutaneous lupus with Elidel. Dermatol Online J. 2002;8(2):25.
78. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004; 51:407-410.
79. Tlacuilo-Parra A, Guevara-Gutiérrez E, Gutiérrez-Murillo F, et al. Pime-crolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatolog y. 2005;44:1564-1568.
80. Sticherling M, Gelbrich G, Rogalski C. Topical pimecrolimus for cutaneous lupus erythematosus results of a double-blind, placebo controlled study. J Deutsch Dermatol Ges. 2007;5:S188-S1889.
81. Barikbin B, Givrad S, Yousef M, et al. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34:776-780.
82. Détran QH, Guay E, Chartier S, Tousignant J. Tacrolimus in dermatology. J Cutan Med Surg. 2001;5:329-335.
83. Graf J, Webb A, Davis J. The use of topical tacrolimus (FK506/Protopic) in cutaneous manifestations of autoimmune diseases. J Clin Rheumatol. 2003;9:310-315.
84. Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: a topic dermatitis and beyond. Int J Clin Pract. 2005;59:969-974.
85. Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin. 2010;28:535-545.
86. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol. 2008;64:337-341.
87. Merrill JT. Topical tacrolimus and pimecrolimus for cutaneous lupus. Curr Rheumatol Rep. 2008;10:263-264.
88. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD002954.
89. Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for fare prevention and long-term disease control in stabilized a topic dermatitis: a randomized comparison of 3 times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008; 58:990-999.
90. Ring J, Möhrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31:185-198.